Ticker Attention Investors: Beware of fraudulent Calls, SMS, Emails, WhatsApp & Telegram messages assuring high returns and / or enticing you to invest money in the name of Aditya Birla Money by installing fake App from spurious links. You can download our Elevate App only from Google Play Store or Apple App Store or login to Elevate Web portal. Click Here to know more.

Aditya Birla Money Limited

Aditya Birla Money Limited

J B Chemicals & Pharmaceuticals Ltd

Symbol : JBCHEPHARM | BSE Code : 506943 | Sector : PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN

1,738.00-31.30 (-1.77%)
01-Aug-2025 | 12:00
Loading

Market Cap (₹ Cr.)

27,168.07
Today’s High / Low
1,769.30
1,731.20
52 Week High / Low
2,030.00
1,385.75
OVERVIEW
  • Open
  • 1,769.30
  • Prev. Close
  • 1,769.30
  • High
  • 1,769.30
  • Low
  • 1,731.20
  • Market Cap (₹ Cr.)
  • 27,168.07
  • 52 Week High
  • 2,030.00
  • 52 Week Low
  • 1,385.75
  • Traded Volume (Lacs)
  • 376,454
  • Traded Value (Cr)
  • Dividend Yield
  • 0.89
  • Face Value
  • 1.00
  • EPS
  • 43.32
  • P/E
  • 40.07
  • Beta (1 year)
  • 1.02
LAST 5 DAYS

1 YEAR RETURN - UNDERPERFORMED THE SENSEX BY 7.73%

  • 02/08/2025 BSE
    -31.50(-1.78)
    Close Price: ₹ 1,735.95
    Volume: 244,393.00

    01-Aug-2025
  • 02/08/2025 BSE
    -15.45(-0.87)
    Close Price: ₹ 1,767.45
    Volume: 5,411.00

    31-Jul-2025
  • 02/08/2025 BSE
    -19.55(-1.08)
    Close Price: ₹ 1,782.90
    Volume: 2,473.00

    30-Jul-2025
  • 02/08/2025 BSE
    93.30(5.46)
    Close Price: ₹ 1,802.45
    Volume: 20,982.00

    29-Jul-2025
  • 02/08/2025 BSE
    3.05(0.18)
    Close Price: ₹ 1,709.15
    Volume: 2,625.00

    28-Jul-2025

1 YEAR RETURN - UNDERPERFORMED THE SENSEX BY 7.73%

  • Stock Absolute
  • 1.75
  • 5.42
  • -9.28
  • 93.78
  • 376.22
  • Returns
  • 1W
  • 1M
  • 1Y
  • 3Y
  • 5Y
  • Sensex Absolute
  • -1.06
  • -3.70
  • -1.55
  • 38.69
  • 118.19
NEWS

J B Chemicals & Pharmaceuticals consolidated net profit rises 14.45% in the June 2025 quarter

31-Jul-2025

Net profit of J B Chemicals & Pharmaceuticals rose 14.45% to Rs 202.38 crore in the quarter ended June 2025 as against Rs 176.83 crore during the previous quarter ended June 2024. Sales rose 8.91% to Rs 1093.94 crore in the quarter ended June 2025 as against Rs 1004.40 crore during the previous quarter ended June 2024.

ParticularsQuarter Ended
Jun. 2025Jun. 2024% Var.
Sales1093.941004.40 9
OPM %27.5027.91 -
PBDT314.31280.62 12
PBT271.61239.84 13
NP202.38176.83 14

31
Jul

J B Chemicals & Pharmaceuticals consolidated net profit rises 14.45% in the June 2025 quarter



31
Jul

JB Chemicals Q1 PAT jumps 14% YoY to Rs 202 cr



30
Jul

J B Chemicals & Pharmaceuticals Ltd - Board Meeting Outcome for 1Unaudited Standalone And Consolidated Financial Results For The Quarter Ended On June 30 2025 Accompanied By Limited Review Report.



FINANCIAL DATA

In Cr.

Mar 2025Mar 2024Mar 2023
SOURCES OF FUNDS :   
Share Capital 15.5715.5215.48
Reserves Total 3,361.632,870.742,426.98
Equity Share Warrants0.000.000.00
Equity Application Money0.000.000.03
Read More
Mar 2025Mar 2024Mar 2023
INCOME :   
Sales Turnover 3,722.923,298.642,884.16
Excise Duty0.000.000.00
Net Sales3,722.923,298.642,884.16
Other Income 34.7434.678.65
Read More
ParticularsJun 2025Mar 2025Dec 2024
Gross Sales 1039.90901.34913.51
Excise Duty 000
Net Sales 1039.90901.34913.51
Other Operating Income 000
Other Income  13.9013.537.16
Read More
Category No. Of Shares Percentage (%)
Total Foreign 28755015 18.43
Total Institutions 30631669 19.63
Total Govt Holding 0 0.00
Total Non Promoter Corporate Holding 651511 0.42
Total Promoters 74481519 47.73
Total Public & others 21,539,210.00 13.80
Total 100.00 100.00
Read More
CORPORATE ACTIONS
Read More
Record Date Ex-Bonus Date Ratio
30-10-1998 05-10-1998 1:1
Read More
Record Date Split Date Face Value Before Face Value After
18-09-2023 18-09-2023 2 1
12-04-2005 05-04-2005 10 2
Read More
ANNOUNCEMENT DATE EX DIVIDEND DATE DIVIDEND (%) DIVIDEND TYPE
14-05-2025 30-07-2025 700 Final
04-02-2025 07-02-2025 850 Interim
17-05-2024 14-08-2024 675 Final
06-02-2024 16-02-2024 550 Interim
24-05-2023 17-08-2023 462.5 Final
PREMIUM (₹) RATIO RECORD DATE EX RIGHTS DATE
nodata
No Data Available!!!
Read More
Read More
FROM DATE EX TO DATE AGENDA
05-10-2025 NA Re-appointment of Mr. Nikhil C...
31-08-2025 NA Re-appointment of Non-Executiv...
20-08-2025 03-09-2025 Public Announcement of open of...
06-08-2025 NA AGM 06/08/2025 Letter to sh...
30-07-2025 NA Pursuant to Regulation 42 of t...
COMPANY INFO

J B Chemicals & Pharmaceuticals Limited (JBC) was originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals on December 18, 1976. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceuticals formulations, herbal remedies and Active Pharmaceutical Ingredients (APIs). The company has manufacturing units at Thane, Belapur, Ankleshwar, Panoli and Daman. The bulk drug plant at Panoli and formulation plant at Daman became operational in Apr.'95. Products like metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine) form a significant part of the company's sales. JBC has its subsidiaries namely Lekar Healthcare Ltd and J.B Life Science Overseas Ltd.

JBC had a tie-up with Justesa Imagen, Spain, to manufacture and market radio diagnostics under the Trazograf brand name. JBC has also diversified into high-growth agro-based products by acquiring McDa Agro (MAL). The products manufactured by MAL complement fertilisers and increase crop productivity. It has entered into a MoU with GNFC to distribute these products locally. The pharmaceutical divisions of Ifiunik Pharmaceuticals and Unique Pharmaceutical Laboratories has been merged into the company with effect from April 2000.

Unique Chemicals (A Division of the company) manufacturing and marketing Bulk Drugs has been awarded Certificate of Suitability to Europeon Pharmacopoeia Monograph for Nifedipine EP from Europeon Directorate for the Quality Medicines.

In Feb. 2002 the company has achieved another break through in its major R & D Activity - Invention biologically active molecules - New Chemical Entity. In 2001-02 the company introduced 3 products Reducin XX and two in the Cholesterol reducing segment i.e., Ifistatin and Vasolip. The company has launched five new products during the year 2003-04 in the global markets to widen its product portfolio. During 2004-05, the company launched new prod

Read More